Locally advanced esophageal adenocarcinoma: Response to neoadjuvant chemotherapy and survival predicted by ^[18F]FDG-PET/CT

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, . Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719–25.
   PubMed Web of Science ®Google Scholar
• Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am 2002;82:729–46.
   PubMedGoogle Scholar
• Sihvo EI, Luostarinen ME, Salo JA. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: A population-based analysis. Am J Gastroenterol 2004;99:419–24.
   PubMedGoogle Scholar
• Vallbohmer D, Holscher AH, DeMeester S, DeMeester T, Salo J, Peters J, . A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 2010; 252:744–9.
   PubMed Web of Science ®Google Scholar
• Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, . Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979–84.
   PubMed Web of Science ®Google Scholar
• Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, . Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003;10:954–60.
   PubMed Web of Science ®Google Scholar
• Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, . Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008;248:902–8.
   PubMed Web of Science ®Google Scholar
• Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, . Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152–60; discussion 1152–60.
   PubMed Web of Science ®Google Scholar
• Sihvo EI, Rasanen JV, Knuuti MJ, Minn HR, Luostarinen ME, Viljanen T, . Adenocarcinoma of the esophagus and the esophagogastric junction: Positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease. J Gastrointest Surg 2004;8:988–96.
   PubMedGoogle Scholar
• Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797–805.
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Holscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, . [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009;250:888–94.
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID, Fritz AP, editors for the American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
   Google Scholar
• Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, . Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3205–9.
   PubMed Web of Science ®Google Scholar
• Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, . Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692–8.
   PubMed Web of Science ®Google Scholar
• Ruol A, Rizzetto C, Castoro C, Cagol M, Alfieri R, Zanchettin G, . Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: Does delayed surgery have an impact on outcome? Ann Surg 2010;252:788–96.
   PubMedGoogle Scholar
• Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, . Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005;242:684–92.
   PubMed Web of Science ®Google Scholar
• Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P, . Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 2007;84:393–400; discussion 400.
   PubMed Web of Science ®Google Scholar
• Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, . Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361–8.
   PubMed Web of Science ®Google Scholar
• Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, . Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: Results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009;32:724–30.
   PubMedGoogle Scholar
• Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, . Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 2010;51:1863–9.
   PubMedGoogle Scholar
• Schmidt M, Bollschweiler E, Dietlein M, Mönig SP, Kobe C, Vallböhmer D, . Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 2009;36:735–44.
   PubMedGoogle Scholar
• Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, . 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101: 1776–85.
   PubMed Web of Science ®Google Scholar
• Fau WH, Fau BB, Zimmermann FF, . Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900–8.
   PubMedGoogle Scholar
• Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, . The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009;115:5184–92.
   PubMedGoogle Scholar
• Brink I, Hentschel M, Bley TA, Walch A, Mix M, Kleimaier M, . Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 2004;30:544–50.
   PubMedGoogle Scholar
• Keyes JW, Jr. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836–9.
   PubMed Web of Science ®Google Scholar
• Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: A systematic review. Radiology 2010;254:707–17.
   PubMed Web of Science ®Google Scholar
• Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: Racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471–8.
   PubMedGoogle Scholar
• American Society of Anesthesiologists [Internet]. Available from: http://www.asahq.org/clinical/physicalstatus.htm (accessed 10 November 2011)
   Google Scholar